Health Sciences Research Awards and Grants
* Award dollars are not included in the clinical trials, as funds are earned based upon completion of study milestones and enrollment.
| Title | Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Screening More Patients for CRC Through Adapting and Refining Targeted Evidence-based Interventions in Rural Settings (SMARTER CRC) | Grant | 70,179.00 | Research | Gloria Coronado | Epidemiology and Biostatistics | Oregon Health and Science University | 05/2024 |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Grant | 200,066.00 | Research | Bettina Cuneo | Surgery | New York University | 05/2024 |
| Targeting Inflammation and Oxidative Stress to Treat Acute Lung Injury With CNP-miR146a | Grant | 124,792.00 | Research | Geoffrey Gurtner | Surgery | Ceria Therapeutics | 05/2024 |
| Targeting P53-Mutated Head and Neck Squamous Cell Carcinoma | Grant | 749,993.00 | Research | Carlos Caulin | Otolaryngology | Arizona Biomedical Research Centre | 05/2024 |
| The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF) | Cooperative Agreement | 29,876.00 | Research | Roderick Tung | COM Phx Internal Medicine | Northwestern University | 05/2024 |
| University of Arizona - Title V Needs Assessment | Contract | 232,000.00 | Other Sponsored Activity | John Ehiri | Public Health Administration | Arizona Department of Health Services | 05/2024 |
| A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527 | Contract | * | Clinical Trial | Jennifer Segar | Cancer Center Division | Aptevo Therapeutics Inc | 04/2024 |
| A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects | Contract | * | Clinical Trial | Scott Sherman | Neurology | PharmaTher Inc (Canada) | 04/2024 |
| A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety,Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab | Contract | * | Clinical Trial | Rachna Shroff | Cancer Center Division | Servier Pharmacueticals | 04/2024 |
| A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen | Contract | * | Clinical Trial | David Labiner | Neurology | Longboard Pharmaceuticals, Inc. | 04/2024 |
| A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients | Contract | * | Clinical Trial | Aaron Scott | Cancer Center Division | Cardiff Oncology, Inc. | 04/2024 |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associate | Contract | * | Clinical Trial | Sachin Chaudhary | Medicine | PPD Investigator Services, LLC. | 04/2024 |
| A Prospective, Open Label, Single-Arm, Multi-Center Study Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment Of Osteochondral Lesions in the Knee | Contract | * | Clinical Trial | Thomas Carter | COM Phx Orthopedics | AlloSource | 04/2024 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act | Contract | * | Clinical Trial | Sasha Taleban | Medicine | IQVIA RDS Inc. | 04/2024 |
| A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled,Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esopha | Contract | * | Clinical Trial | Geoffrey Block | Liver Research Institute | Galectin Therapeutics Inc. | 04/2024 |
| Advanced Methods and Software for Trial Sequential Analysis in Living Systematic Reviews | Grant | 364,114.00 | Research | Lifeng Lin | Epidemiology and Biostatistics | National Library of Medicine | 04/2024 |
| Biological Function and Regulation of PRMT9 in Synapse Development | Grant | 128,937.00 | Research | Shenfeng Qiu | COM Phx Basic Medical Sci | Beckman Research Institute of The City of Hope | 04/2024 |
| Computer Modeling of Myosin Binding Protein C and Its Effects on Cardiac Contraction | Grant | 126,750.00 | Research | Brett Colson | Cellular & Molecular Medicine | Case Western Reserve University | 04/2024 |
| Connexins as Potential Biomarkers and Therapeutic Targets for Vascular Malformation | Grant | 15,299.00 | Research | Jose Ek Vitorin | Physiology | University of California, Irvine | 04/2024 |
| Deep-Learning Based Pharmacokinetic Model for Vancomycin | Grant | 29,054.00 | Research | Bijun Kannadath | COM Phx Internal Medicine | Houston Methodist Research Institute | 04/2024 |
* Award dollars are not included in the clinical trials, as funds are earned based upon completion of study milestones and enrollment.